Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Post by Mugen1996on Jan 28, 2010 6:46pm

365 Views

Post# 16730468

Presentation

TH has just posted on their site the latest Presentation at Biotech Showcase 2010

https://www.theratech.com/docs/en/corpo/2010-01-04_TH_PresentationCorpo.pdf

Advisory Committee : Q1 2010
PDUFA date : Still March 29th

I hope PDUFA date won't be delayed 'cause of the Advisory reschedule! If so, the Advisory commettee has to meet btw February 25th and March 28th!

Bullboard Posts

Options trading in a volatile macro environment